Physician profile
Peter J Bigham
NPI 1134154040
$2,028.86
in general payments reported to CMS, 2019-2025
22 companies · $333 in 2025
The $333 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $91.68 · 2022: $167 · 2023: $472 · 2024: $153 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $338.59 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $264.75 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $214.87 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $185.87 | 2019-2025 | |
| Boston Scientific Corporation | $182.79 | 2023-2025 | Watchman Access System, General - Therapies |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.17 | 2019-2023 | Lifevest |
| Amgen INC. | $107.47 | 2019-2022 | |
| Philips North America LLC | $83.60 | 2023-2025 | Ecc Solutions |
| Medtronic, INC. | $79.08 | 2022-2025 | Corevalve Evolut R, Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.44 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $53.63 | 2024-2025 | Opsynvi, Opsumit |
| Angiodynamics, INC. | $50.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.54 | 2019-2022 | |
| Biosense Webster, INC. | $35.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.87 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $29.00 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $21.27 | 2019 | |
| Cvrx, INC. | $20.64 | 2025 | Barostim Neo System |
| Aegerion Pharmaceuticals, INC. | $17.55 | 2019 | |
| Amarin Pharma, INC. | $17.54 | 2020 | |
| Cardinal Health 200 LLC | $15.68 | 2019 | |
| Irhythm Technologies, INC. | $14.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bigham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.